Armenia vs Belarus: Average cost of drugs for extensively drug-resistant tuberculosis

Armenia
4,190 constant 2022 US$
in 2024
Belarus
4,600 constant 2022 US$
in 2023
Armenia rank
16th
Belarus rank
13th

Average cost of drugs for extensively drug-resistant tuberculosis over time

  • Armenia
  • Belarus
02.0k4.0k6.0k8.0k201720202024

How they compare

Belarus currently reports 4,600 constant 2022 US$ against 4,190 constant 2022 US$ in Armenia, a difference of 410 constant 2022 US$.

That makes Belarus's figure about 1.1 times Armenia's.

Armenia ranks 16th and Belarus ranks 13th of 56 countries.

Belarus has averaged higher in every one of the 2 decades both report.

Head to head by decade

Decade Armenia Belarus Difference Ahead
2010s 4,900 constant 2022 US$ 7,650 constant 2022 US$ 2,750 constant 2022 US$ Belarus
2020s 5,600 constant 2022 US$ 5,867 constant 2022 US$ 266.67 constant 2022 US$ Belarus

Averages of every year both report within each decade.

Frequently asked questions

Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Armenia or Belarus?
Belarus, at 4,600 constant 2022 US$ against 4,190 constant 2022 US$ in Armenia as of 2023.
What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Armenia and Belarus?
410 constant 2022 US$, with Belarus ahead.
How do Armenia and Belarus rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
Armenia ranks 16th and Belarus ranks 13th of 56 countries.
Where does this data come from?
WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.

Individual pages

About this data

Indicator
Average cost of drugs for extensively drug-resistant tuberculosis
Unit
constant 2022 US$
Source
WHO (2025) – with minor processing by Our World in Data
Licence
CC BY 4.0 (Our World in Data)
Coverage
56 places, 394 data points, 2017–2024
Last refreshed

Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.